

Respiratory & Immune Support Protocol

Evidence-based probiotic, supplement, and dietary strategies to strengthen your respiratory defenses through the gut-lung axis

What This Protocol Addresses

Respiratory infections -- from the common cold and influenza to more serious lower tract illnesses -- are among the most common causes of illness worldwide. While most people think of respiratory health as strictly a lung issue, a growing body of research reveals that the gut microbiome plays a central role in regulating immune defenses throughout the body, including in the airways. This connection, known as the gut-lung axis, means that what happens in your gut directly influences how well your immune system fights respiratory pathogens.

The Gut-Lung Axis: Five Immune Pathways

Pathway	Mechanism	Evidence
SCFA-mediated lung protection	Gut-derived butyrate and propionate suppress pulmonary inflammation via GPCRs (free fatty acid receptors) and HDAC inhibition	Verma 2024: SCFAs modulate inflammatory gene expression in pulmonary leukocytes
sIgA mucosal defense	Probiotics enhance secretory IgA production at mucosal surfaces, including airways	Zhang 2021: BI-04 yogurt increased sIgA from 389 to 529 mg/dL
Alveolar macrophage activation	Gut microbiota metabolites prime alveolar macrophages to produce type I IFNs and IFN-gamma	Garcia-Castillo 2020: L. rhamnosus CRL1505 enhanced macrophage antiviral responses
Immune cell migration	T cells and dendritic cells educated in the gut migrate to respiratory mucosa	Espirito Santo 2021: diet-gut-lung immune crosstalk via migrating immune cells
Innate immunity priming	Probiotics upregulate baseline nasal CXCL8 and innate antiviral readiness	Turner 2017: BI-04 raised nasal CXCL8 (90 vs 58 pg/mL) before virus challenge

Respiratory Infections Disrupt Your Gut -- and Vice Versa

Woodall et al. (2022) conducted a systematic review of 11 studies and found that respiratory tract infections cause significant gut microbiome changes: Shannon diversity dropped by 1.45 units ($p < 0.0001$), with depletion of beneficial Lachnospiraceae, Ruminococcaceae, and Ruminococcus and enrichment of pathogenic Enterococcus. This bidirectional disruption means protecting your gut during cold and flu season is not just about digestion -- it is about defending your lungs.

Probiotics for Respiratory Infections: The Meta-Analytic Evidence

Multiple large-scale meta-analyses confirm that oral probiotic supplementation reduces both the incidence and duration of respiratory tract infections. The effect is consistent across different strains, doses, and populations, and is supported by the highest level of evidence -- Cochrane systematic reviews.

Meta-Analysis	Studies / Participants	Key Findings
Hao 2015 (Cochrane)	13 RCTs; 3,720 participants	Probiotics reduced URTI episodes: OR 0.53 (0.37-0.76); duration MD -1.89 days; antibiotic prescriptions OR 0.65 (0.45-0.94); school absence OR 0.10 (0.02-0.47)
Coleman 2022 (Adv Nutr)	42 manuscripts; 9,179 adults	Risk of ≥ 1 RTI: RR 0.91 (0.84-0.98); total sick days: rate ratio 0.77 (0.71-0.83); duration: Hedges' g = -0.23; severity: Hedges' g = -0.16
Li 2020 (EBCAM)	6 RCTs; 1,551 adults	Incidence: RR 0.77 (0.68-0.87); episode rate: ratio 0.72 (0.60-0.86); mean duration reduced MD -2.66 days
Laursen 2018 (Eur J Pediatr)	15 RCTs; 5,121 children in day care	LGG reduced RTI duration: MD -0.78 days (3 RCTs, n=1,295); strain-specific evidence for <i>L. rhamnosus</i> GG

What the Numbers Mean

The Cochrane review's OR of 0.53 means probiotics roughly halved the odds of experiencing a URTI episode. Combined with 23% fewer total sick days (Coleman 2022) and nearly 2 fewer days per cold episode, the evidence strongly supports daily probiotic supplementation as a practical strategy for respiratory defense -- especially during cold and flu season.

Strain Spotlight: Bifidobacterium animalis subsp. lactis BI-04

BI-04 is one of the most well-studied probiotic strains specifically for respiratory immune defense, with evidence from both a controlled rhinovirus challenge study and a clinical RCT in adults.

Experimental Rhinovirus Challenge (Turner 2017)

In a landmark study, 152 seronegative volunteers were supplemented with BI-04 or placebo for 28 days, then deliberately challenged with rhinovirus RV-A39. The probiotic group showed significantly higher baseline nasal CXCL8 levels (90 vs 58 pg/mL; $p = 0.04$), indicating primed innate immunity before the virus even arrived. After infection, the BI-04 group had reduced nasal virus titres and fewer subjects shedding virus (76% vs 91%; $p = 0.04$). The probiotic also dampened the inflammatory CXCL8 response to infection ($p = 0.03$), suggesting better-controlled immunity.

Clinical RCT in Haze-Exposed Adults (Zhang 2021)

A randomized clinical trial in 136 adults living in a haze-covered region of Northern China tested yogurt supplemented with BI-04 (250g daily) for 12 weeks. The results were striking:

Outcome	BI-04 Yogurt	Control Yogurt	Significance
Common cold incidence	Reduced	Reference	OR 0.38 (0.17-0.81; $p = 0.013$)
Influenza-like illness	Reduced	Reference	OR 0.32 (0.11-0.97; $p = 0.045$)
URTI duration (days)	1.23 +/- 2.73	4.78 +/- 5.09	Significant reduction
URTI severity score	3.58 +/- 7.12	11.37 +/- 11.73	Significant reduction
IFN-gamma (pg/mL)	139.49 +/- 59.49	113.45 +/- 65.12	Significant increase
slgA (mg/dL)	529.19 +/- 91.70	388.88 +/- 53.83	Significant increase

Why BI-04 Stands Out

BI-04 is unique because it has been tested in both experimental virus challenge AND a real-world clinical trial. The mechanism is now clear: it primes nasal innate immunity (higher baseline CXCL8), enhances systemic immune markers (IFN-gamma, slgA), and reduces both viral shedding and symptomatic disease. This makes it a top-tier strain for respiratory immune support.

Additional Probiotic Strains for Respiratory Defense

Lactobacillus rhamnosus GG (LGG)

LGG is the most widely studied probiotic strain in the world, with over 30 years of clinical research. For respiratory health specifically, it has Cochrane-level evidence showing a 47% reduction in URTI episodes (OR 0.53) and nearly 2 fewer days of illness per episode. In children attending daycare, LGG reduced RTI duration by 0.78 days across three RCTs (Laursen 2018). Its immune mechanisms include enhanced intestinal barrier function, increased sIgA production, and promotion of Th1-type immune responses that are critical for antiviral defense.

Lactobacillus rhamnosus CRL1505 (Immunobiotic)

CRL1505 is a specialized immunobiotic strain researched extensively for its gut-lung axis effects. When given orally, it activates alveolar macrophages -- the frontline immune cells in the lungs -- and enhances their production of type I interferons (IFN-alpha/beta) and IFN-gamma in response to viral challenge. In animal models of RSV infection, CRL1505 increased expression of antiviral genes (IFITM3, MX1, OAS1), reduced viral load, and improved lung function. Importantly, it has been used successfully in children to reduce the incidence and morbidity of viral airway infections (Garcia-Castillo 2020, Kitazawa & Villena 2014).

Choosing Your Probiotic Strategy

Strain	Best For	Key Evidence	Dose
B. lactis BI-04	Year-round respiratory defense; adults in polluted environments	Rhinovirus challenge: 76% vs 91% shedding; RCT: cold OR 0.38	2-10 billion CFU/day
L. rhamnosus GG	Children and adults; general URTI prevention	Cochrane: OR 0.53 for URTI episodes; MD -1.89 days	10 billion CFU/day
L. rhamnosus CRL1505	Enhanced antiviral lung immunity; children	Activates alveolar macrophages, enhances IFN production	Per product label
Multi-strain formulation	Broad immune support; combining mechanisms	Coleman 2022: consistent effects across strain combinations	10-25 billion CFU/day

Vitamin D: The Respiratory Immune Essential

Vitamin D is arguably the single most important micronutrient for respiratory immune defense. Two landmark individual participant data (IPD) meta-analyses by the Martineau group provide the strongest evidence for any vitamin-respiratory infection link.

Meta-Analysis	Scale	Overall Effect	Best Subgroup
Martineau 2017 (BMJ)	25 RCTs; 11,321 participants; IPD	Adjusted OR 0.88 (0.81-0.96); 12% risk reduction	Severely deficient (<25 nmol/L): OR 0.30 -- 70% risk reduction; daily/weekly dosing: OR 0.81
Jolliffe 2021 (Lancet D&E;)	46 RCTs; 75,541 participants	OR 0.92 (0.86-0.99); 8% risk reduction	Daily dosing: OR 0.78 (22% reduction); 400-1000 IU/day: OR 0.70 (30% reduction); children 1-16 years: OR 0.71 (29% reduction)

Critical Dosing Insight

Both meta-analyses found that daily or weekly dosing is essential -- bolus (large single-dose) supplementation does NOT protect against respiratory infections (Martineau 2017: bolus OR 0.97, non-significant). The optimal dose is 400-1000 IU daily (OR 0.70 in the Jolliffe 2021 update), though those with confirmed deficiency may need 2000-4000 IU daily to reach adequate levels. Those who are severely deficient (< 25 nmol/L or < 10 ng/mL) benefit the most -- with a 70% reduction in respiratory infection risk.

Vitamin D supports respiratory immunity through multiple mechanisms: it induces production of the antimicrobial peptide cathelicidin (LL-37) which directly kills pathogens, it enhances macrophage pathogen-killing ability, it promotes anti-inflammatory cytokine production, and it supports epithelial barrier integrity in the airways.

Vitamin C: Duration Reducer and Stress Shield

The Cochrane review by Hemila and Chalker (2013) -- the definitive analysis of vitamin C and the common cold -- examined 29 trials with 11,306 participants and revealed a nuanced picture.

Population	Prevention Effect	Duration Effect
General population	NOT effective for prevention (RR 0.97; 95% CI 0.94-1.00)	Adults: colds 8% shorter (3-12%); Children: colds 14% shorter (7-21%)
Physically stressed (marathoners, skiers, soldiers)	52% reduction in cold incidence (RR 0.48; 95% CI 0.35-0.64)	Severity also significantly reduced
Children (1-2 g/day)	See general population	18% shorter colds -- the largest pediatric effect

The Abioye 2021 BMJ Global Health meta-analysis confirmed these findings, showing vitamin C reduced ARI risk (RR 0.96; 0.93-0.99; $p = 0.01$) and symptom duration by 9%. The effect was stronger among men and in middle-income countries.

Practical Vitamin C Guidance

Regular daily supplementation (500-1000 mg) is more effective than waiting until you are already sick. If you exercise intensely, work outdoors in cold weather, or are under physical stress, the evidence strongly supports vitamin C supplementation -- with a 52% reduction in cold incidence in these populations. For children, 500 mg to 1 g daily can shorten colds by nearly a full day.

Zinc: The Rapid Recovery Mineral

Zinc has the largest effect on respiratory symptom duration of any single micronutrient studied. Two key analyses demonstrate its power:

Zinc Acetate Lozenges (Hemila 2017)

An individual patient data meta-analysis of 3 RCTs (199 patients) using 80-92 mg/day of elemental zinc as zinc acetate lozenges found a recovery rate ratio of 3.1 (95% CI 2.1-4.7) -- meaning zinc patients recovered 3 times faster than placebo. By day 5, 70% of zinc patients had recovered compared to just 27% on placebo. The number needed to treat was only 2.3, making this one of the most efficient interventions available for the common cold.

Zinc in the Micronutrient Meta-Analysis (Abioye 2021)

The comprehensive BMJ Global Health meta-analysis found that zinc did not significantly reduce ARI incidence, but it shortened symptom duration by an extraordinary 47% (95% CI -73% to -21%; $p = 0.0004$). This was by far the largest duration reduction among all micronutrients studied (vitamin D: -6%, vitamin C: -9%, zinc: -47%).

Important: Zinc Timing and Form

Zinc lozenges must be started within 24 hours of symptom onset for maximum benefit. Zinc acetate lozenges are preferred because they release ionic zinc in the oral cavity where it can directly inhibit viral replication. Do not use zinc nasal sprays, which have been linked to loss of smell. For daily preventive use, 15-30 mg of elemental zinc (as zinc picolinate, citrate, or gluconate) is sufficient. Higher therapeutic doses (80+ mg) should only be used short-term during active illness.

N-Acetylcysteine (NAC): The Symptom Shield

NAC is a powerful antioxidant and precursor to glutathione, the body's master antioxidant. A landmark multicenter RCT by De Flora et al. (1997) demonstrated its remarkable ability to reduce symptomatic influenza illness.

The Landmark NAC Trial

Parameter	Detail
Study design	Randomized, double-blind, placebo-controlled; 20 Italian centers
Participants	262 subjects (78% aged 65+; 62% with chronic diseases)
Intervention	NAC 600 mg twice daily for 6 months (winter season)
Infection rate	Similar seroconversion in both groups -- NAC did NOT prevent infection
Symptomatic disease	Only 25% of infected NAC-treated subjects developed symptoms vs 79% placebo
Symptoms	Both local and systemic symptoms sharply and significantly reduced
Immune markers	Progressive shift from anergy to normoergy (improved cell-mediated immunity)

Why NAC Is Remarkable

NAC does not prevent you from being infected -- the virus still enters your system. But it dramatically reduces the chance that infection becomes symptomatic illness. Only 25% of infected NAC-treated subjects developed symptoms compared to 79% on placebo. This is essentially an immune resilience effect: NAC enhances your body's ability to fight the virus without developing the full inflammatory cascade of symptoms. The mechanism involves enhanced glutathione levels, improved cell-mediated immunity, and reduced oxidative stress-driven inflammation.

Elderberry (*Sambucus nigra*): The Botanical Immune Booster

Hawkins et al. (2019) published a meta-analysis of randomized, controlled clinical trials evaluating black elderberry supplementation for upper respiratory symptoms. The analysis included 180 participants and found that elderberry supplementation substantially reduced upper respiratory symptoms, yielding a large mean effect size. The effect was consistent regardless of vaccination status or whether the symptoms were caused by influenza or the common cold.

Elderberry works through multiple mechanisms: it contains anthocyanins and flavonoids that inhibit viral entry and replication, it stimulates cytokine production (particularly IL-6 and TNF-alpha for acute immune activation), and it has direct anti-inflammatory properties. The typical effective dose in clinical trials is 600-900 mg of standardized elderberry extract daily, or 15 mL of elderberry syrup taken 4 times daily at symptom onset.

Elderberry Best Practices

Start elderberry at the first sign of cold or flu symptoms for maximum benefit. It can also be taken preventively during cold/flu season at a lower dose (300-600 mg daily). Choose standardized extracts rather than homemade preparations, as raw elderberries contain compounds that can cause GI distress. Elderberry is generally safe but should be used with caution in autoimmune conditions, as its immune-stimulating properties could theoretically exacerbate autoimmune flares.

The Respiratory Immune Support Stack

Based on the combined evidence, here is a tiered supplement strategy for respiratory immune support. Tier 1 forms the evidence-based foundation. Tiers 2 and 3 add layers of protection based on individual needs.

Tier	Supplement	Daily Dose	Key Evidence
1 (Foundation)	Vitamin D3	1000-2000 IU (up to 4000 IU if deficient)	Martineau 2017: OR 0.88; Jolliffe 2021: OR 0.70 at 400-1000 IU daily
1 (Foundation)	Probiotic (BI-04 or LGG)	2-10 billion CFU	Cochrane: OR 0.53 for URTI; Turner 2017: reduced viral shedding
1 (Foundation)	Vitamin C	500-1000 mg	Cochrane: 8-14% shorter colds; Abioye 2021: RR 0.96 for ARI
2 (Enhanced)	Zinc (preventive)	15-30 mg elemental	Abioye 2021: -47% symptom duration; supports immune cell function
2 (Enhanced)	NAC	600 mg twice daily	De Flora 1997: 25% vs 79% symptomatic disease in infected subjects
2 (Enhanced)	Prebiotic fiber	5-10 g daily (inulin, GOS, or FOS)	Feeds SCFA-producing bacteria; SCFAs suppress lung inflammation
3 (Seasonal)	Elderberry extract	600-900 mg at symptom onset	Hawkins 2019: large effect size for reducing respiratory symptoms
3 (Seasonal)	Zinc acetate lozenges	80-92 mg/day (during illness only)	Hemila 2017: 3x faster recovery; NNT 2.3 on day 5

Phase 1: Build Your Respiratory Shield (Months 1–3)

The first three months focus on establishing a strong gut-lung axis foundation. This means building a diverse, SCFA-producing gut microbiome while ensuring your key immune-supporting nutrients are at optimal levels.

Daily Protocol

Morning: Probiotic containing *B. lactis* BI-04 or *L. rhamnosus* GG (2-10 billion CFU) with breakfast. Take vitamin D3 (1000-2000 IU) with a meal containing fat for absorption. Vitamin C 500 mg.

With meals: Prebiotic-rich foods -- aim for diversity. Onions, garlic, leeks, asparagus, bananas, oats, and Jerusalem artichokes provide inulin and FOS that feed your SCFA-producing gut bacteria.

Evening: NAC 600 mg with dinner. Additional vitamin C 500 mg if desired (split dosing improves absorption). Zinc 15-30 mg with food to avoid nausea.

Dietary Framework: The Respiratory Microbiome Diet

Food Category	Examples	Why It Helps
Prebiotic fibers	Onions, garlic, leeks, asparagus, artichokes, bananas, oats	Feed Bifidobacterium, Lactobacillus, and SCFA producers
Fermented foods	Yogurt, kefir, sauerkraut, kimchi, miso, kombucha	Live cultures enhance mucosal immunity; fermented dairy matrix improves probiotic delivery (Coleman 2022)
Colorful fruits and vegetables	Berries, citrus, bell peppers, leafy greens, sweet potatoes	Polyphenols and vitamin C support antioxidant defense and immune cell function
Omega-3 rich foods	Fatty fish (salmon, mackerel, sardines), walnuts, flaxseeds	Resolve inflammation; support balanced immune response
Mushrooms	Shiitake, maitake, reishi, lion's mane	Beta-glucans stimulate innate immune cells (macrophages, NK cells)

The 30-Plant Challenge

Aim to eat 30 different plant foods per week. Research shows that gut microbiome diversity -- the key to a strong gut-lung axis -- correlates directly with dietary plant diversity. This includes fruits, vegetables, legumes, whole grains, nuts, seeds, herbs, and spices. Each one feeds different beneficial bacterial species.

Phase 2: Optimize and Defend (Months 4-6+)

After three months, your gut microbiome should be shifting toward a more diverse, SCFA-rich profile. Phase 2 focuses on seasonal strategies, acute illness protocols, and long-term immune optimization.

Seasonal Defense Strategy

Season	Strategy	Rationale
Pre-cold/flu season (Sep-Oct)	Increase probiotic dose; start NAC 600 mg 2x/day; check vitamin D levels	Proactive immune priming before peak exposure; correct deficiency before winter
Peak season (Nov-Mar)	Maintain full supplement stack; add elderberry 300-600 mg daily as preventive	Maximum immune vigilance during highest transmission period
At symptom onset	Start zinc acetate lozenges (80-92 mg/day); increase elderberry to 600-900 mg; add vitamin C to 2g/day	Zinc lozenges within 24 hours: 3x faster recovery (Hemila 2017)
During active illness	Continue all supplements; zinc lozenges for up to 5 days; increase fluids; rest	Support immune function while minimizing symptom severity and duration
Recovery	Maintain probiotics to restore gut microbiome; return to baseline dosing	RTIs deplete gut Lachnospiraceae/Ruminococcaceae (Woodall 2022); recovery support needed

When You Get Sick: Acute Illness Protocol

Acute Respiratory Illness Action Plan

1. Start zinc acetate lozenges immediately (within 24 hours of first symptom) -- 80 to 92 mg elemental zinc/day in divided doses every 2-3 hours while awake. Continue for up to 5 days. 2. Increase elderberry to 600-900 mg standardized extract or 15 mL syrup 4 times daily. 3. Increase vitamin C to 1-2 g/day in divided doses. 4. Continue NAC 600 mg twice daily -- this is when its symptom-reducing effect is most valuable. 5. Continue your probiotic -- it protects your gut from the infection-driven dysbiosis documented by Woodall 2022. 6. Rest, hydrate, and avoid intense exercise until symptoms resolve.

Tracking Your Progress

Unlike conditions with specific biomarkers, respiratory immune health is best tracked through practical outcomes over time. Keep a simple log to identify patterns and improvements.

Marker	What It Tells You	Frequency / Target
Number of colds/year	Overall susceptibility	Track annually; average adult: 2-4/year; aim to reduce by 25-50%
Cold duration (days)	Immune response efficiency	Track each episode; target < 5 days (vs typical 7-10)
Sick days from work/school	Functional impact	Track annually; goal: fewer missed days each year
Antibiotic prescriptions	Secondary infection frequency	Track annually; probiotics reduced by 35% (Cochrane)
Vitamin D level (25-OH-D)	Immune readiness	Check yearly; target 40-60 ng/mL (100-150 nmol/L)
Symptom severity (1-10 scale)	How sick you feel during illness	Rate each episode; lower scores suggest better immune control
Recovery time	How quickly you bounce back	Track each episode; target full recovery within 5-7 days
GI symptoms during illness	Gut-lung axis disruption	Note any GI symptoms during respiratory illness

Timeline Expectations

Weeks 1-4: Improved digestion and energy as gut microbiome begins shifting. Months 1-3: Building immune foundation; may not notice changes until the next cold season. Months 3-6: First measurable differences -- expect fewer, shorter, and milder colds. After one full year: the strongest evidence comes from studies lasting 6-12 months. Compare your annual cold frequency, duration, and severity to previous years. The gut-lung axis responds to consistent, sustained intervention.

Sources

1. Verma et al. (2024). Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis. ACS Omega. DOI: 10.1021/acsomega.3c05846
2. Espirito Santo et al. (2021). Gut Microbiota, in the Halfway between Nutrition and Lung Function. Nutrients. DOI: 10.3390/nu13051716
3. Woodall et al. (2022). Respiratory tract infections and gut microbiome modifications: A systematic review. PLoS One. DOI: 10.1371/journal.pone.0262057
4. Hao et al. (2015). Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. DOI: 10.1002/14651858.CD006895.pub3
5. Coleman et al. (2022). Orally Ingested Probiotics, Prebiotics, and Synbiotics as Countermeasures for RTIs in Nonelderly Adults. Adv Nutr. DOI: 10.1093/advances/nmac086
6. Li et al. (2020). Probiotics for Preventing Upper Respiratory Tract Infections in Adults. Evid Based Complement Alternat Med. DOI: 10.1155/2020/8734140
7. Laursen & Hojsak (2018). Probiotics for respiratory tract infections in children attending day care centers. Eur J Pediatr. DOI: 10.1007/s00431-018-3167-1
8. Turner et al. (2017). Effect of probiotic BI-04 on innate inflammatory response and viral shedding in experimental rhinovirus infection. Benef Microbes. DOI: 10.3920/BM2016.0160
9. Zhang et al. (2021). Effect of fermented milk with BI-04 on URTI in adults in Northern China. Pharm Biol. DOI: 10.1080/13880209.2021.1929344
10. Garcia-Castillo et al. (2020). Alveolar Macrophages Are Key Players in Respiratory Antiviral Immunity Induced by *L. rhamnosus* CRL1505. Front Immunol. DOI: 10.3389/fimmu.2020.568636
11. Martineau et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: IPD meta-analysis. BMJ. DOI: 10.1136/bmj.i6583
12. Jolliffe et al. (2021). Vitamin D supplementation to prevent acute respiratory infections: aggregate data meta-analysis. Lancet Diabetes Endocrinol. DOI: 10.1016/S2213-8587(21)00051-6
13. Hemila & Chalker (2013). Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. DOI: 10.1002/14651858.CD000980.pub4
14. Hemila et al. (2017). Zinc Acetate Lozenges May Improve the Recovery Rate of Common Cold Patients. Open Forum Infect Dis. DOI: 10.1093/ofid/ofx059
15. Abioye et al. (2021). Effect of micronutrient supplements on influenza and other respiratory tract infections. BMJ Glob Health. DOI: 10.1136/bmjgh-2020-003176
16. De Flora et al. (1997). Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term NAC treatment. Eur Respir J. DOI: 10.1183/09031936.97.10071535

Disclaimer

This protocol is provided for educational and informational purposes only. It is not intended as medical advice and should not replace consultation with a qualified healthcare provider. Respiratory infections can range from mild to life-threatening, and some require prompt medical attention. Always consult your physician before starting any supplement regimen, especially if you are taking medications, have an autoimmune condition, are pregnant or nursing, or have a chronic respiratory condition such as asthma or COPD. Individual results may vary. The information presented is based on peer-reviewed research available at the time of writing and may be updated as new evidence emerges.

BiomeGuide.com